EGFR and non-small cell lung carcinoma: However, numerous secondary EGFR mutations, such as C797, G796, L792, L718, and G724 site mutations, have evolved to evade inhibition and mediate resistance to osimertinib in NSCLC harboring EGFR T790M mutants (Thress et al., 2015; Zheng et al., 2017; Fuchs et al., 2021; Chen et al., 2017; Pisapia et al., 2019; Bersanelli et al., 2016; Peled et al., 2017).